Published in Cancer Weekly, November 1st, 2005
Subject to shareholder approval, investors in the financing will also receive warrants to purchase 620,452 ADSs at an exercise price of $9.69 per share. The closing is subject to certain conditions precedent to the closing. The purchase price is subject to reduction of 20% if the company's shareholders do not approve the issuance of the warrants within 180 days. Funds managed by Great Point Partners, LLC, were the lead investors in the transaction. Rodman & Renshaw,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.